We assume that immune checkpoint molecules, including TIGIT/CD226/CD112/CD155, have an essential role in the regulation of the Th1 predominance, which is initiated by intrinsic factors released by the poorly developed placenta during EO preeclampsia. Here, PVR is linked to preeclampsia.